158 related articles for article (PubMed ID: 27466504)
1. Prognostic Impact of Activated Leucocyte Cell Adhesion Molecule (ALCAM/CD166) in Infantile Neuroblastoma.
Wachowiak R; Mayer S; Kaifi J; Gebauer F; Izbicki JR; Lacher M; Bockhorn M; Tachezy M
Anticancer Res; 2016 Aug; 36(8):3991-5. PubMed ID: 27466504
[TBL] [Abstract][Full Text] [Related]
2. Loss of ALCAM expression is linked to adverse phenotype and poor prognosis in breast cancer: a TMA-based immunohistochemical study on 2,197 breast cancer patients.
Burandt E; Bari Noubar T; Lebeau A; Minner S; Burdelski C; Jänicke F; Müller V; Terracciano L; Simon R; Sauter G; Wilczak W; Lebok P
Oncol Rep; 2014 Dec; 32(6):2628-34. PubMed ID: 25270339
[TBL] [Abstract][Full Text] [Related]
3. Predictive impact of activated leukocyte cell adhesion molecule (ALCAM/CD166) in breast cancer.
Ihnen M; Müller V; Wirtz RM; Schröder C; Krenkel S; Witzel I; Lisboa BW; Jänicke F; Milde-Langosch K
Breast Cancer Res Treat; 2008 Dec; 112(3):419-27. PubMed ID: 18172759
[TBL] [Abstract][Full Text] [Related]
4. Activated leukocyte cell adhesion molecule (ALCAM) is a marker of recurrence and promotes cell migration, invasion, and metastasis in early-stage endometrioid endometrial cancer.
Devis L; Moiola CP; Masia N; Martinez-Garcia E; Santacana M; Stirbat TV; Brochard-Wyart F; García Á; Alameda F; Cabrera S; Palacios J; Moreno-Bueno G; Abal M; Thomas W; Dufour S; Matias-Guiu X; Santamaria A; Reventos J; Gil-Moreno A; Colas E
J Pathol; 2017 Mar; 241(4):475-487. PubMed ID: 27873306
[TBL] [Abstract][Full Text] [Related]
5. Activated leukocyte cell adhesion molecule (CD166)--its prognostic power for colorectal cancer patients.
Tachezy M; Zander H; Gebauer F; Marx A; Kaifi JT; Izbicki JR; Bockhorn M
J Surg Res; 2012 Sep; 177(1):e15-20. PubMed ID: 22482754
[TBL] [Abstract][Full Text] [Related]
6. Biologic role of activated leukocyte cell adhesion molecule overexpression in breast cancer cell lines and clinical tumor tissue.
Hein S; Müller V; Köhler N; Wikman H; Krenkel S; Streichert T; Schweizer M; Riethdorf S; Assmann V; Ihnen M; Beck K; Issa R; Jänicke F; Pantel K; Milde-Langosch K
Breast Cancer Res Treat; 2011 Sep; 129(2):347-60. PubMed ID: 20972617
[TBL] [Abstract][Full Text] [Related]
7. Prognostic significance of ALCAM (CD166/MEMD) expression in cutaneous melanoma patients.
Donizy P; Zietek M; Halon A; Leskiewicz M; Kozyra C; Matkowski R
Diagn Pathol; 2015 Jul; 10():86. PubMed ID: 26134500
[TBL] [Abstract][Full Text] [Related]
8. ALCAM (CD166) expression as novel prognostic biomarker for pancreatic neuroendocrine tumor patients.
Tachezy M; Zander H; Marx AH; Gebauer F; Rawnaq T; Kaifi JT; Sauter G; Izbicki JR; Bockhorn M
J Surg Res; 2011 Oct; 170(2):226-32. PubMed ID: 21816425
[TBL] [Abstract][Full Text] [Related]
9. Expression of ALCAM (CD166) and PD-L1 (CD274) independently predicts shorter survival in malignant pleural mesothelioma.
Inaguma S; Lasota J; Wang Z; Czapiewski P; Langfort R; Rys J; Szpor J; Waloszczyk P; Okoń K; Biernat W; Ikeda H; Schrump DS; Hassan R; Miettinen M
Hum Pathol; 2018 Jan; 71():1-7. PubMed ID: 28811252
[TBL] [Abstract][Full Text] [Related]
10. [Expression of activated leukocyte cell adhesion molecule in breast cancer. Predictability of the response to taxane-free chemotherapy].
Kilic E; Milde-Langosch K; Müller V; Wirtz R; Ihnen M
Pathologe; 2008 Nov; 29 Suppl 2():347-52. PubMed ID: 18810438
[TBL] [Abstract][Full Text] [Related]
11. Clinical implication of CD166 expression in salivary gland tumor.
Andisheh-Tadbir A; Ashraf MJ; Khademi B; Ahmadi S
Tumour Biol; 2015 Apr; 36(4):2793-9. PubMed ID: 25472586
[TBL] [Abstract][Full Text] [Related]
12. ALCAM, activated leukocyte cell adhesion molecule, influences the aggressive nature of breast cancer cells, a potential connection to bone metastasis.
Davies S; Jiang WG
Anticancer Res; 2010 Apr; 30(4):1163-8. PubMed ID: 20530423
[TBL] [Abstract][Full Text] [Related]
13. Increased expression of ALCAM/CD166 in pancreatic cancer is an independent prognostic marker for poor survival and early tumour relapse.
Kahlert C; Weber H; Mogler C; Bergmann F; Schirmacher P; Kenngott HG; Matterne U; Mollberg N; Rahbari NN; Hinz U; Koch M; Aigner M; Weitz J
Br J Cancer; 2009 Aug; 101(3):457-64. PubMed ID: 19603023
[TBL] [Abstract][Full Text] [Related]
14. Detection of activated leukocyte cell adhesion molecule in the serum of breast cancer patients and implications for prognosis.
Witzel I; Schröder C; Müller V; Zander H; Tachezy M; Ihnen M; Jänicke F; Milde-Langosch K
Oncology; 2012; 82(6):305-12. PubMed ID: 22555284
[TBL] [Abstract][Full Text] [Related]
15. Glycosylation-dependent binding of galectin-8 to activated leukocyte cell adhesion molecule (ALCAM/CD166) promotes its surface segregation on breast cancer cells.
Fernández MM; Ferragut F; Cárdenas Delgado VM; Bracalente C; Bravo AI; Cagnoni AJ; Nuñez M; Morosi LG; Quinta HR; Espelt MV; Troncoso MF; Wolfenstein-Todel C; Mariño KV; Malchiodi EL; Rabinovich GA; Elola MT
Biochim Biophys Acta; 2016 Oct; 1860(10):2255-68. PubMed ID: 27130882
[TBL] [Abstract][Full Text] [Related]
16. Prognostic Significance of Activated Leukocyte Cell Adhesion Molecule (ALCAM) in Association with Promoter Methylation of the ALCAM Gene in Breast Cancer.
Jeong YJ; Oh HK; Park SH; Bong JG
Molecules; 2018 Jan; 23(1):. PubMed ID: 29315254
[TBL] [Abstract][Full Text] [Related]
17. Activated leukocyte cell adhesion molecule expression is up-regulated in the development of endometrioid carcinoma.
Liang S; Huang C; Jia S; Wang B
Int J Gynecol Cancer; 2011 Apr; 21(3):523-8. PubMed ID: 21430457
[TBL] [Abstract][Full Text] [Related]
18. Subcellular localization of activated leukocyte cell adhesion molecule is a molecular predictor of survival in ovarian carcinoma patients.
Mezzanzanica D; Fabbi M; Bagnoli M; Staurengo S; Losa M; Balladore E; Alberti P; Lusa L; Ditto A; Ferrini S; Pierotti MA; Barbareschi M; Pilotti S; Canevari S
Clin Cancer Res; 2008 Mar; 14(6):1726-33. PubMed ID: 18347173
[TBL] [Abstract][Full Text] [Related]
19. Dual knockdown of Galectin-8 and its glycosylated ligand, the activated leukocyte cell adhesion molecule (ALCAM/CD166), synergistically delays in vivo breast cancer growth.
Ferragut F; Cagnoni AJ; Colombo LL; Sánchez Terrero C; Wolfenstein-Todel C; Troncoso MF; Vanzulli SI; Rabinovich GA; Mariño KV; Elola MT
Biochim Biophys Acta Mol Cell Res; 2019 Aug; 1866(8):1338-1352. PubMed ID: 30905597
[TBL] [Abstract][Full Text] [Related]
20. P21 and CD166 as predictive markers of poor response and outcome after fluorouracil-based chemoradiotherapy for the patients with rectal cancer.
Sim SH; Kang MH; Kim YJ; Lee KW; Kim DW; Kang SB; Eom KY; Kim JS; Lee HS; Kim JH
BMC Cancer; 2014 Apr; 14():241. PubMed ID: 24708484
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
